R 0016/11 () of 23.3.2012

European Case Law Identifier: ECLI:EP:BA:2012:R001611.20120323
Date of decision: 23 March 2012
Case number: R 0016/11
Petition for review of: T 1710/09
Application number: 01201913.9
IPC class: A61K 31/663
Language of proceedings: EN
Distribution: B
Download and more information:
Decision text in EN (PDF, 145 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Alendronate for use in the treatment of osteoporosis
Applicant name: Merck Sharp & Dohme Corp.
Opponent name: PLIVA, Farmaceutska Industrija Dionicko Drustvo + AWD.pharma GmbH & Co. KG
STADA Arzneimittel AG
Hexal AG + Sandoz AG
Arrow International Ltd.
betapharm Arzneimittel GmbH
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Gedeon Richter Plc.
Generics [UK] Ltd. et al
STADA Arzneimittel GmbH
"Interpharm" ProduktionsgmbH
BIOGARAN
Tecnimede, Sociedade Tecnico-Medicinal, S.A.
ACTAVIS GROUP
Board: EBA
Headnote: -
Relevant legal provisions:
European Patent Convention Art 112a(2)
European Patent Convention Art 113
European Patent Convention Art 76
European Patent Convention Art 123(2)
Keywords: New objection raised by the Board (no)- denial of the right to be heard (no)- petition for review clearly unallowable
Catchwords:

-

Cited decisions:
R 0012/09
R 0022/10
R 0006/11
Citing decisions:
R 0003/13
T 2023/09
T 0253/10

12 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

Case Law Book: V Priority

General Case Law